日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors.

Copanlisib 与 Nivolumab 联合治疗晚期实体瘤患者的安全性和有效性：一项 Ib 期研究

期刊:Cancer Research Communications
影响因子:3.3
doi:10.1158/2767-9764.CRC-24-0407
Carneiro Benedito A, Jotte Robert M, Gabrail Nashat Y, Wentzel Kristopher, Huang Funan, Chaturvedi Shalini, Weispfenning Anke, Hiemeyer Florian, Morcos Peter N, Mongay Soler Lidia, Childs Barrett H, Hansen Aaron R
肿瘤
发表日期：2025
文献求助 收藏

Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis

新型寡核苷酸端粒酶抑制剂伊美替司他致心律失常风险低：一项转化分析

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.70169
Lennox, Ashley L; Sun, Libo; Huang, Fei; Behrs, Melissa Kelly; Kleiman, Robert; Xue, Hongqi; Bhise, Neha; Wan, Ying; Berry, Tymara; Feller, Faye; Morcos, Peter N
发表日期：2025
文献求助 收藏

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes

免疫原性对寡核苷酸端粒酶抑制剂伊美替司他（Imetelstat）在低危骨髓增生异常综合征中的药代动力学、疗效和安全性无影响

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.70431
Lennox, Ashley L; Huang, Fei; González-Sales, Mario; Wan, Ying; Sun, Libo; Berry, Tymara; Feller, Faye; Morcos, Peter N
免疫/内分泌
发表日期：2025
文献求助 收藏

CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

CHRONOS-4：一项评估copanlisib联合利妥昔单抗免疫化疗治疗复发性惰性B细胞淋巴瘤的3期研究

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2024013236
Zinzani, Pier Luigi; Wang, Huaqing; Feng, Jifeng; Kim, Tae Min; Tao, Rong; Zhang, Huilai; Fogliatto, Laura; Maluquer Artigal, Clara; Özcan, Muhit; Yanez, Eduardo; Kim, Won Seog; Kirtbaya, Dmitry; Kriachok, Iryna; Maciel, Felipe; Xue, Hongwei; Bouabdallah, Krimo; Phelps, Charles; Chaturvedi, Shalini; Weispfenning, Anke; Morcos, Peter N; Odongo, Fatuma; Buvaylo, Viktoriya; Childs, Barrett H; Dreyling, Martin; Matasar, Matthew; Ghione, Paola
B细胞
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2024
文献求助 收藏

Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitor

伊美替司他（一种首创的寡核苷酸端粒酶抑制剂）的群体药代动力学

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.13160
González-Sales, Mario; Lennox, Ashley L; Huang, Fei; Pamulapati, Chandra; Wan, Ying; Sun, Libo; Berry, Tymara; Kelly Behrs, Melissa; Feller, Faye; Morcos, Peter N
发表日期：2024
文献求助 收藏

Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science

伊美替司他，一种新型的、首创的端粒酶抑制剂：作用机制、临床和转化科学

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.70076
Lennox, Ashley L; Huang, Fei; Behrs, Melissa Kelly; González-Sales, Mario; Bhise, Neha; Wan, Ying; Sun, Libo; Berry, Tymara; Feller, Faye; Morcos, Peter N
发表日期：2024
文献求助 收藏

Model-informed approach to support pediatric dosing for the pan-PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors

基于模型的方法支持泛PI3K抑制剂copanlisib在复发/难治性实体瘤儿童和青少年中的儿科给药方案

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13523
Morcos, Peter N; Schlender, Jan; Burghaus, Rolf; Moss, Jonathan; Lloyd, Adam; Childs, Barrett H; Macy, Margaret E; Reid, Joel M; Chung, John; Garmann, Dirk
发表日期：2023
文献求助 收藏

Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial

循环游离DNA作为晚期ALK+非小细胞肺癌患者的预后生物标志物：全球III期ALEX试验

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-21-2840
Dziadziuszko, Rafal; Peters, Solange; Mok, Tony; Camidge, D Ross; Gadgeel, Shirish M; Ou, Sai-Hong Ignatius; Konopa, Krzysztof; Noé, Johannes; Nowicka, Malgorzata; Bordogna, Walter; Morcos, Peter N; Smoljanovic, Vlatka; Shaw, Alice T
肺癌
肿瘤
肿瘤免疫
ALK
细胞生物学
发表日期：2022
文献求助 收藏

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Glofitamab，一种新型的二价CD20靶向T细胞结合双特异性抗体，可诱导复发或难治性B细胞淋巴瘤患者获得持久的完全缓解：一项I期临床试验

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.20.03175
Hutchings, Martin; Morschhauser, Franck; Iacoboni, Gloria; Carlo-Stella, Carmelo; Offner, Fritz C; Sureda, Anna; Salles, Gilles; Martínez-Lopez, Joaquín; Crump, Michael; Thomas, Denise N; Morcos, Peter N; Ferlini, Cristiano; Bröske, Ann-Marie E; Belousov, Anton; Bacac, Marina; Dimier, Natalie; Carlile, David J; Lundberg, Linda; Perez-Callejo, David; Umaña, Pablo; Moore, Tom; Weisser, Martin; Dickinson, Michael J
B细胞
T细胞
淋巴瘤
CD20
T细胞
细胞生物学
CD2
免疫/内分泌
发表日期：2021
文献求助 收藏

Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer

对阿来替尼进行药代动力学分析，以促进确定其作为间变性淋巴瘤激酶阳性非小细胞肺癌一线治疗的最佳剂量。

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12702
Hsu, Joy C; Jaminion, Felix; Guerini, Elena; Balas, Bogdana; Bordogna, Walter; Morcos, Peter N; Frey, Nicolas
肺癌
肿瘤
肿瘤免疫
信号转导
淋巴瘤
细胞生物学
发表日期：2021
文献求助 收藏